J
James A. Bonner
Researcher at University of Alabama at Birmingham
Publications - 252
Citations - 17463
James A. Bonner is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Radiation therapy & Cetuximab. The author has an hindex of 56, co-authored 237 publications receiving 16175 citations. Previous affiliations of James A. Bonner include University of Alabama & University of Michigan.
Papers
More filters
Journal ArticleDOI
Biological Effective Radiation Dose for Multiple Myeloma Palliation
TL;DR: In this article , the influence of dose/fractionation and other factors pertinent to individualizing therapy for palliation in multiple myeloma was reviewed. But, the authors did not identify any significant toxicity.
Journal ArticleDOI
HiJAKing Immunotherapy-Resistant Melanoma for a Cure
TL;DR: In this paper , the authors provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients, and provide a review of ICB-resistant patients with advanced melanoma.
Journal ArticleDOI
Long-term results of a phase I/II trial of the addition of celecoxib to chemoradiotherapy for locally advanced or recurrent squamous cell carcinoma of the head-and-neck
Andrew M. McDonald,Roger Ove,James A. Bonner,Lisle Nabell,William R. Carroll,Nasser Said Al-Naief,Margaret Brandwein-Gensler,Sharon A. Spencer +7 more
TL;DR: Celecoxib appears to be a safe addition to cisplatin-based chemoradiotherapy for the primary treatment of locoregionally advanced SCCHN and initial response rates were encouraging, and survival compared favorably with contemporary trials.
Phase I S tudy o f A nti-Epidermal G rowth F actor R eceptor Antibody C etuximab i n C ombination W ith R adiation Therapy i n P atients W ith A dvanced H ead a nd N eck C ancer
Francisco Robert,Mark P. Ezekiel,Sharon A. Spencer,Ruby F. Meredith,James A. Bonner,M. B. Khazaeli,Mansoor N. Saleh,Delicia Carey,Albert F. LoBuglio,Richard H. Wheeler,Michael R. Cooper,Harlan W. Waksal +11 more
TL;DR: In this paper, the authors evaluated the safety, pharmacokinetics, and efficacy of a chimeric anti-epidermal growth factor receptor monoclonal antibody, cetuximab, in combination with radiation therapy (RT) in patients with advanced squamous cell carcinoma of the head and neck.
Journal ArticleDOI
Society of Chairs of Academic Radiation Oncology Programs–Endorsed Radiation Oncology Department Review Process
Charles R. Thomas,James A. Bonner,Stephen M. Hahn,Theodore S. Lawrence,Fei-Fei Liu,Silvia C. Formenti +5 more
TL;DR: This research attacked the mode of cell reprograming using positron emission tomography and X-ray radiolysis to identify the “spiking” activity in the nucleus of the T cells of the immune system.